mergers & acquisitions
GSK to Acquire IDRx in $1.15B Deal
GSK will gain IDRx's lead candidate, the KIT inhibitor IDRX-42, an investigational treatment for KIT-mutant gastrointestinal stromal tumors.
Wuxi AppTec Selling Cell, Gene Therapy Unit to Altaris
The transaction, expected to close in the first half of 2025, will not affect the firm's other contract research business units.
Novartis Acquires Kate Therapeutics in $1.1B Deal
The acquisition is poised to strengthen Novartis' position in the gene therapy market for neuromuscular conditions.
AbbVie to Buy Aliada Therapeutics for $1.4B in Cash
Through the acquisition, AbbVie will gain Aliada's lead asset, a beta-amyloid-targeting drug in a Phase I trial designed to cross the blood-brain barrier.
Lyell Immunopharma to Acquire ImmPact Bio, Discontinue Several Pipeline Programs
The firm will stop developing several of its own cell therapies to focus on advancing IMPT-314, a CAR T-cell therapy it is gaining by purchasing ImmPact.